Control of clofibrate toxicity in uremic hypertriglyceridemia

Area of Science:

• Pharmacology
• Nephrology
• Clinical Therapeutics

Background:

• Clofibrate effectively reduces serum triglyceride (TG) levels in patients with normal renal function.
• Standard clofibrate doses (1.5-2.0 gm/day) can cause muscle toxicity and elevated creatine phosphokinase (CPK) in patients with long-term renal failure.
• Severely uremic patients exhibit significantly prolonged plasma clofibrate clearance, up to seven times the normal rate.

Purpose of the Study:

• To determine an effective and safe clofibrate dosage for hypertriglyceridemic hemodialysis patients.
• To assess the impact of a reduced clofibrate dose on serum TG and CPK levels in this population.
• To compare serum clofibrate levels in hemodialysis patients on a reduced dose with those in non-uremic patients on a standard dose.

Main Methods:

• Administered a reduced weekly clofibrate dose (1.0-1.5 gm/wk) to hypertriglyceridemic hemodialysis patients.
• Monitored serum triglyceride (TG) and creatine phosphokinase (CPK) levels.
• Measured serum clofibrate levels and compared them to historical data from non-uremic patients.

Main Results:

• A reduced clofibrate dose of 1.0-1.5 gm/wk significantly lowered serum TG levels by 28% (p < 0.02) in hemodialysis patients.
• This reduced dosage regimen effectively avoided muscle toxicity and elevated CPK levels.
• Serum clofibrate levels in hemodialysis patients on the reduced dose were comparable to those in hypertriglyceridemic non-uremic patients receiving standard doses.

Conclusions:

• Clofibrate dosage can be safely adjusted for hemodialysis patients to achieve therapeutic triglyceride reduction without toxicity.
• Monitoring serum CPK and TG levels is crucial for optimizing clofibrate therapy in patients with renal failure.
• A lower weekly clofibrate dose (1.0-1.5 gm/wk) is effective and safe for managing hypertriglyceridemia in hemodialysis patients.